Dr. Cui was selected for the 2023 Wing Tat Lee Awards for collaboration with a Chinese University.
Eric Fu will be leading a project focus on a novel human lncRNA as a potential therapeutic target for fetal hemoglobin induction in patients with sickle cell disease and β-thalassemia.
Julia Garland and Jordan Brady join to Cui Lab as research volunteers.
Hajar joins to Cui Lab as a postdoc research fellow.
Welcome Kelly Liu to the Cui Lab!
Kelly Liu joined to the lab as a Master student. She will lead a project focusing on the role of HMI Lnc-RNA in globin regulation and erythroid differentiation.
Dr. Cui received a grant from Doris Duke Charitable Foundation for the collaboration project "Interactions between fetal hemoglobin regulation network" with the Mount Sinai School of Medicine.
Congratulations! Nicole has been selected as an NIDDK Distinguished Postbaccalaureate Scholar.
She was one of five finalists selected to participate in the NIDDK Distinguished Postbaccalaureate Scholar Program.
Her interview greatly impressed the search committee and she was finally awarded a postbac position through this program.
Raymon Chen received the fall 2021 UROP Student Research Awards. He will be leading a project focus on a novel human lncRNA with an important role in the regulation of fetal hemoglobin (HbF) with the goal of acquiring a new therapeutic target for HbF induction in patients with SCD and β-thalassemia. Targeting lncRNAs therapeutically has the advantages of increased specificity, different RNA-directed therapeutic approaches, and the possibility of small molecule inhibitors. The proposed studies would allow him to gain skills and knowledge of various cutting-edge techniques, such as lentivirus- mediated RNA interference and gene delivery to human hematopoietic stem or progenitor cells.
Dr. Cui received a supplemental grant from Doris Duke Charitable Foundation for sickle cell disease research.
Congratulations! Nicole Nguyen and Nika Kozlov both received the Summer 2021 UROP Awards.
Nicole's project focused on determining optimal conditions of DMNT1 Inhibitor, decitabine, to induce maximal fetal hemoglobin expression in human erythroid progenitor cells.
Nika's project focused on evaluating the in vivo effects of PGC-1a agonists, ZLN005 and SR-18292, in sickle cell disease mice.